GlassScriptPhysician profile
Dhara H Patel
NPI 1841815610
$836.07
in general payments reported to CMS, 2019-2025
17 companies · $290 in 2025
The $290 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $263 · 2024: $283 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $836.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $119.72 | 2023 | Valtoco |
| Tersera Therapeutics LLC | $96.95 | 2025 | Xermelo |
| Abbvie INC. | $83.84 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $58.78 | 2023-2024 | Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.50 | 2023-2025 | Jardiance |
| Inspire Medical Systems, INC. | $55.38 | 2024 | Inspire |
| Novo Nordisk INC | $54.94 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $40.64 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $40.13 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $35.63 | 2024-2025 | Spravato |
| Ardelyx, INC. | $33.93 | 2025 | Ibsrela |
| Lilly USA, LLC | $33.07 | 2023-2024 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $30.91 | 2023-2025 | Cologuard Collection Kit |
| Genzyme Corporation | $28.97 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.32 | 2024-2025 | Xifaxan |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $22.05 | 2023 | |
| Beta Bionics, INC. | $16.31 | 2023 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dhara Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.